Company profile: Forty Seven
1.1 - Company Overview
Company description
- Provider of clinical-stage immuno-oncology therapies targeting cancer immune evasion pathways, based on technology licensed from Stanford University. Lead program 5F9 is a monoclonal antibody against the CD47 receptor, a 'don't eat me' signal that cancer cells commandeer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Forty Seven
Gradalis
HQ: United States
Website
- Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gradalis company profile →
Elevation Oncology
HQ: United States
Website
- Description: Provider of precision medicines as a clinical-stage biopharmaceutical company, developing EO-3021, an antibody-drug conjugate targeting Claudin 18.2 for advanced/metastatic solid tumors, particularly gastric and gastroesophageal junction adenocarcinoma, and Seribantumab, an anti-HER3 monoclonal antibody for NRG1 fusion-positive tumors; conducts clinical trials and offers compassionate use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elevation Oncology company profile →
Exact Sciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including Cologuard, a non-invasive at-home stool-based colorectal cancer screening test for individuals 45+, Riskguard hereditary cancer testing, Oncotype DX Breast Recurrence Score to assess recurrence and guide treatment for ER+/HER2- breast cancer, OncoExTra genomic profiling for therapy selection in advanced/metastatic cancer, and under-development Breast Radiation Score and colorectal cancer blood test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Sciences company profile →
Attovia Therapeutics
HQ: United States
Website
- Description: Provider of a biologics platform and pipeline of biotherapeutics for immune-mediated diseases, featuring ATTOBODY to generate binders and biparatopic biologics as alternatives to IgG-based medicines; programs include ATTO-1310 (IL31), ATTO-002 (IL31 x IL13), ATTO-004 (novel GPCR), and ATTO-005 (IBD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attovia Therapeutics company profile →
Theranostics Health
HQ: United States
Website
- Description: Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranostics Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Forty Seven
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Forty Seven
2.2 - Growth funds investing in similar companies to Forty Seven
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Forty Seven
4.2 - Public trading comparable groups for Forty Seven
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →